Evaluation the efficacy and safety of N-acetylcysteine inhalation spray in controlling the symptoms of patients with COVID-19: An open-label randomized controlled clinical trial

J Med Virol. 2023 Jan;95(1):e28393. doi: 10.1002/jmv.28393.

Abstract

The aim of this study was to evaluate the effect and safety of N-acetylcysteine (NAC) inhalation spray in the treatment of patients with coronavirus disease 2019 (COVID-19). This randomized controlled clinical trial study was conducted on patients with COVID-19. Eligible patients (n = 250) were randomly allocated into the intervention group (routine treatment + NAC inhaler spray one puff per 12 h, for 7 days) or the control group who received routine treatment alone. Clinical features, hemodynamic, hematological, biochemical parameters and patient outcomes were assessed and compared before and after treatment. The mortality rate was significantly higher in the control group than in the intervention group (39.2% vs. 3.2%, p < 0.001). Significant differences were found between the two groups (intervention and control, respectively) for white blood cell count (6.2 vs. 7.8, p < 0.001), hemoglobin (12.3 vs. 13.3, p = 0.002), C-reactive protein (CRP: 6 vs. 11.5, p < 0.0001) and aspartate aminotransferase (AST: 32 vs. 25.5, p < 0.0001). No differences were seen for hospital length of stay (11.98 ± 3.61 vs. 11.81 ± 3.52, p = 0.814) or the requirement for intensive care unit (ICU) admission (7.2% vs. 11.2%, p = 0.274). NAC was beneficial in reducing the mortality rate in patients with COVID-19 and inflammatory parameters, and a reduction in the development of severe respiratory failure; however, it did not affect the length of hospital stay or the need for ICU admission. Data on the effectiveness of NAC for Severe Acute Respiratory Syndrome Coronavirus-2 is limited and further research is required.

Keywords: N-acetylcysteine; Severe Acute Respiratory Syndrome Coronavirus-2; clinical trial.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Acetylcysteine* / administration & dosage
  • Acetylcysteine* / adverse effects
  • Administration, Inhalation
  • COVID-19* / therapy
  • Humans
  • Length of Stay
  • Nebulizers and Vaporizers
  • Oral Sprays*
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Acetylcysteine
  • Oral Sprays

Associated data

  • IRCT/IRCT20080901001165N55